Nikulski Financial Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,915 shares of the company’s stock after selling 151 shares during the quarter. Nikulski Financial Inc.’s holdings in Johnson & Johnson were worth $317,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Atlantic Private Wealth LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $32,000. 25 LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $55,000. Horizons Wealth Management increased its holdings in Johnson & Johnson by 1,730.0% during the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after acquiring an additional 346 shares in the last quarter. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $66,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $109,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on JNJ shares. Barclays raised their price target on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Wells Fargo & Company decreased their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. HSBC assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 price target on the stock. Finally, Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $169.19.
Johnson & Johnson Trading Up 0.4 %
NYSE JNJ opened at $153.00 on Monday. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The company’s 50 day moving average price is $161.23 and its 200 day moving average price is $162.45. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market capitalization of $397.64 billion, a price-to-earnings ratio of 11.36, a PEG ratio of 3.09 and a beta of 0.55.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 36.71%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.59 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 10.1 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.11%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.
Insider Activity
In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- 10 Best Airline Stocks to Buy
- Bargain Alert: Crocs a Footwear Brand With Single Digit P/E Ratio
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 10/16 – 10/20
- How to Most Effectively Use the MarketBeat Earnings Screener
- Institutions Buy Consumer Staples, is the Bottom in?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
